Arcus Biosciences, Inc. (RCUS) Financial Statements

Income statement

Metric	TTM	2025	2024	2023	2022
Revenue
Total Revenue	117.0M	247.0M	258.0M	117.0M	112.0M
Cost of Revenue	7.0M	10.0M	—	—	—
Gross Profit	110.0M	237.0M	258.0M	117.0M	112.0M
Operating Expenses
R&D Expense	497.0M	523.0M	448.0M	340.0M	288.0M
SG&A Expense	106.0M	110.0M	120.0M	117.0M	104.0M
General & Admin Expense	106.0M	110.0M	120.0M	117.0M	104.0M
Selling & Marketing Expense	—	—	—	—	—
Other Expenses	(7.0M)	(10.0M)	20.0M	—	—
Total Operating Expenses	596.0M	623.0M	588.0M	457.0M	392.0M
Cost and Expenses	603.0M	633.0M	588.0M	457.0M	392.0M
Operating Income (EBIT)	(486.0M)	(386.0M)	(330.0M)	(340.0M)	(280.0M)
Non-Operating
Interest Income	58.0M	41.0M	52.0M	41.0M	16.0M
Interest Expense	23.0M	8.0M	4.0M	2.0M	2.0M
Net Interest Income	35.0M	33.0M	48.0M	39.0M	14.0M
Other Non-Op Income/Expense	34.0M	33.0M	47.0M	39.0M	14.0M
Non-Operating Income (excl Interest)	(57.0M)	(41.0M)	(51.0M)	(41.0M)	(16.0M)
EBT (Pre-Tax Income)	(452.0M)	(353.0M)	(283.0M)	(301.0M)	(266.0M)
Income Tax Expense	—	—	1.0M	6.0M	1.0M
Bottom Line
Net Income	(452.0M)	(353.0M)	(283.0M)	(307.0M)	(267.0M)
Earnings from Cont. Ops	(452.0M)	(353.0M)	(284.0M)	(307.0M)	(267.0M)
Earnings from Discont. Ops	—	—	—	—	—
Bottom Line Net Income	(452.0M)	(353.0M)	(283.0M)	(307.0M)	(267.0M)
Per Share
Basic EPS	($3.93)	($3.29)	($3.14)	($4.15)	($3.71)
Diluted EPS	($3.93)	($3.29)	($3.14)	($4.15)	($3.71)
Revenue Per Share	$0.93	$2.30	$2.86	$1.58	$1.56
Shares
Basic Shares Outstanding	126.1M	107.4M	90.1M	74.0M	72.0M
Diluted Shares Outstanding	126.1M	107.4M	90.1M	74.0M	72.0M
Profitability Metrics
EBITDA	(419.0M)	(335.0M)	(269.0M)	(291.0M)	(258.0M)
D&A	10.0M	10.0M	10.0M	8.0M	6.0M
EBIT	(429.0M)	(345.0M)	(279.0M)	(299.0M)	(264.0M)

As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026